Real-time assessment of HER2 status in circulating tumor cells of breast cancer patients: Methods of detection and clinical implications
The human epidermal growth factor receptor 2 (HER2) plays a central role in breast cancer (BC). Therefore, it is critical to develop a method that can capture its spatial and temporal heterogeneity. Nowadays, therapeutic decisions for BC patients relies on evaluation of HER2 status from tissue biops...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-12-01
|
| Series: | The Journal of Liquid Biopsy |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2950195423001170 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846160197939101696 |
|---|---|
| author | Eleonora Nicolò Mara Serena Serafini Laura Munoz-Arcos Letizia Pontolillo Elisabetta Molteni Nadia Bayou Eleni Andreopoulou Giuseppe Curigliano Carolina Reduzzi Massimo Cristofanilli |
| author_facet | Eleonora Nicolò Mara Serena Serafini Laura Munoz-Arcos Letizia Pontolillo Elisabetta Molteni Nadia Bayou Eleni Andreopoulou Giuseppe Curigliano Carolina Reduzzi Massimo Cristofanilli |
| author_sort | Eleonora Nicolò |
| collection | DOAJ |
| description | The human epidermal growth factor receptor 2 (HER2) plays a central role in breast cancer (BC). Therefore, it is critical to develop a method that can capture its spatial and temporal heterogeneity. Nowadays, therapeutic decisions for BC patients relies on evaluation of HER2 status from tissue biopsies using immunohistochemistry and in situ hybridization. Nevertheless, considering the technical and logistical challenges associated with tissue biopsies, there is an unmet need for a non-invasive and accurate approach to obtain real-time assessment of HER2 status. In this context, circulating biomarkers, particularly circulating tumor cells (CTCs), emerged as promising candidates. HER2 assessment on CTCs can be performed at genomic, transcriptomic, and protein levels on both bulk CTCs and at the single-cell resolution. However, the main limitation of the literature to date is the lack of a consistent definition of HER2-positive CTCs, which poses a major challenge for both, future research and clinical applications. Several studies revealed discordance in HER2 status between the primary tumor and corresponding CTCs. For instance, HER2-positive CTCs have been detected among patients with HER2-negative BC and vice versa. As a result, researchers have evaluated the prognostic and predictive value of HER2 status in CTCs, both in the early and metastatic settings, to increase the possibility of using anti-HER2 therapy also for these patients and to dissect mechanisms of treatment resistance. This review aims to provide an overview of the methods to determine HER2 status in CTCs and to summarize the evidence and future perspective on how CTCs-HER2 assessment can be integrated into the clinical management of BC patients. |
| format | Article |
| id | doaj-art-89eab89b25b84e08a2924abb642ee2ea |
| institution | Kabale University |
| issn | 2950-1954 |
| language | English |
| publishDate | 2023-12-01 |
| publisher | Elsevier |
| record_format | Article |
| series | The Journal of Liquid Biopsy |
| spelling | doaj-art-89eab89b25b84e08a2924abb642ee2ea2024-11-22T07:41:23ZengElsevierThe Journal of Liquid Biopsy2950-19542023-12-012100117Real-time assessment of HER2 status in circulating tumor cells of breast cancer patients: Methods of detection and clinical implicationsEleonora Nicolò0Mara Serena Serafini1Laura Munoz-Arcos2Letizia Pontolillo3Elisabetta Molteni4Nadia Bayou5Eleni Andreopoulou6Giuseppe Curigliano7Carolina Reduzzi8Massimo Cristofanilli9Division of New Drugs and Early Drug Development, European Institute of Oncology IRCCS, Milan, Italy; Department of Oncology and Hematology-Oncology, University of Milan, Milan, Italy; Department of Medicine, Division of Hematology-Oncology, Weill Cornell Medicine, New York, NY, USA; Corresponding author. Department of Medicine Division of Hematology-Oncology, 1300 York Avenue, New York, NY, 10065, USA.Department of Medicine, Division of Hematology-Oncology, Weill Cornell Medicine, New York, NY, USADepartment of Medicine, Division of Hematology-Oncology, Weill Cornell Medicine, New York, NY, USADepartment of Medicine, Division of Hematology-Oncology, Weill Cornell Medicine, New York, NY, USA; Medical Oncology Department, Catholic University of Sacred Heart, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, ItalyDepartment of Medicine, Division of Hematology-Oncology, Weill Cornell Medicine, New York, NY, USA; Department of Medicine, University of Udine, Via Chiusaforte, Udine, ItalyDepartment of Medicine, Division of Hematology-Oncology, Weill Cornell Medicine, New York, NY, USA; Human Genetics Laboratory (LR99ES10), Faculty of Medicine of Tunis, University of Tunis El Manar, Tunis, 2092, TunisiaDepartment of Medicine, Division of Hematology-Oncology, Weill Cornell Medicine, New York, NY, USADivision of New Drugs and Early Drug Development, European Institute of Oncology IRCCS, Milan, Italy; Department of Oncology and Hematology-Oncology, University of Milan, Milan, ItalyDepartment of Medicine, Division of Hematology-Oncology, Weill Cornell Medicine, New York, NY, USADepartment of Medicine, Division of Hematology-Oncology, Weill Cornell Medicine, New York, NY, USAThe human epidermal growth factor receptor 2 (HER2) plays a central role in breast cancer (BC). Therefore, it is critical to develop a method that can capture its spatial and temporal heterogeneity. Nowadays, therapeutic decisions for BC patients relies on evaluation of HER2 status from tissue biopsies using immunohistochemistry and in situ hybridization. Nevertheless, considering the technical and logistical challenges associated with tissue biopsies, there is an unmet need for a non-invasive and accurate approach to obtain real-time assessment of HER2 status. In this context, circulating biomarkers, particularly circulating tumor cells (CTCs), emerged as promising candidates. HER2 assessment on CTCs can be performed at genomic, transcriptomic, and protein levels on both bulk CTCs and at the single-cell resolution. However, the main limitation of the literature to date is the lack of a consistent definition of HER2-positive CTCs, which poses a major challenge for both, future research and clinical applications. Several studies revealed discordance in HER2 status between the primary tumor and corresponding CTCs. For instance, HER2-positive CTCs have been detected among patients with HER2-negative BC and vice versa. As a result, researchers have evaluated the prognostic and predictive value of HER2 status in CTCs, both in the early and metastatic settings, to increase the possibility of using anti-HER2 therapy also for these patients and to dissect mechanisms of treatment resistance. This review aims to provide an overview of the methods to determine HER2 status in CTCs and to summarize the evidence and future perspective on how CTCs-HER2 assessment can be integrated into the clinical management of BC patients.http://www.sciencedirect.com/science/article/pii/S2950195423001170Circulating tumor cellsBreast cancerHER2HER2-LowPrognostic valuePredictive value |
| spellingShingle | Eleonora Nicolò Mara Serena Serafini Laura Munoz-Arcos Letizia Pontolillo Elisabetta Molteni Nadia Bayou Eleni Andreopoulou Giuseppe Curigliano Carolina Reduzzi Massimo Cristofanilli Real-time assessment of HER2 status in circulating tumor cells of breast cancer patients: Methods of detection and clinical implications The Journal of Liquid Biopsy Circulating tumor cells Breast cancer HER2 HER2-Low Prognostic value Predictive value |
| title | Real-time assessment of HER2 status in circulating tumor cells of breast cancer patients: Methods of detection and clinical implications |
| title_full | Real-time assessment of HER2 status in circulating tumor cells of breast cancer patients: Methods of detection and clinical implications |
| title_fullStr | Real-time assessment of HER2 status in circulating tumor cells of breast cancer patients: Methods of detection and clinical implications |
| title_full_unstemmed | Real-time assessment of HER2 status in circulating tumor cells of breast cancer patients: Methods of detection and clinical implications |
| title_short | Real-time assessment of HER2 status in circulating tumor cells of breast cancer patients: Methods of detection and clinical implications |
| title_sort | real time assessment of her2 status in circulating tumor cells of breast cancer patients methods of detection and clinical implications |
| topic | Circulating tumor cells Breast cancer HER2 HER2-Low Prognostic value Predictive value |
| url | http://www.sciencedirect.com/science/article/pii/S2950195423001170 |
| work_keys_str_mv | AT eleonoranicolo realtimeassessmentofher2statusincirculatingtumorcellsofbreastcancerpatientsmethodsofdetectionandclinicalimplications AT maraserenaserafini realtimeassessmentofher2statusincirculatingtumorcellsofbreastcancerpatientsmethodsofdetectionandclinicalimplications AT lauramunozarcos realtimeassessmentofher2statusincirculatingtumorcellsofbreastcancerpatientsmethodsofdetectionandclinicalimplications AT letiziapontolillo realtimeassessmentofher2statusincirculatingtumorcellsofbreastcancerpatientsmethodsofdetectionandclinicalimplications AT elisabettamolteni realtimeassessmentofher2statusincirculatingtumorcellsofbreastcancerpatientsmethodsofdetectionandclinicalimplications AT nadiabayou realtimeassessmentofher2statusincirculatingtumorcellsofbreastcancerpatientsmethodsofdetectionandclinicalimplications AT eleniandreopoulou realtimeassessmentofher2statusincirculatingtumorcellsofbreastcancerpatientsmethodsofdetectionandclinicalimplications AT giuseppecurigliano realtimeassessmentofher2statusincirculatingtumorcellsofbreastcancerpatientsmethodsofdetectionandclinicalimplications AT carolinareduzzi realtimeassessmentofher2statusincirculatingtumorcellsofbreastcancerpatientsmethodsofdetectionandclinicalimplications AT massimocristofanilli realtimeassessmentofher2statusincirculatingtumorcellsofbreastcancerpatientsmethodsofdetectionandclinicalimplications |